Titan Pharmaceuticals, Inc. (TTNP): ANSOFF MATRIX [Dec-2025 Updated]

You're looking at a development-stage biotech, Titan Pharmaceuticals, Inc. (TTNP), where the focus is clearly on platform advancement, not immediate profit-the Q2 2025 EPS of -$0.65 tells that story defintely. As an analyst who has mapped out growth for firms much larger, I find the Ansoff Matrix the clearest way to see their strategy for the ProNeura long-term drug delivery platform. It shows they are aggressively pursuing market penetration to maximize licensed revenue, while simultaneously hunting for new geographies and pushing the Nalmefene implant through development. Plus, they are funding these efforts, using the $1 Million April 2025 financing for market access and the $600,000 June 2025 private placement for formulation optimization; you need to see the concrete actions planned for each quadrant below to gauge the risk-reward profile.

Titan Pharmaceuticals, Inc. (TTNP) - Ansoff Matrix: Market Penetration

You're looking at how Titan Pharmaceuticals, Inc. (TTNP) can maximize sales from its existing product, Probuphine, in its current licensed territories. This is about digging deeper into the markets where the product already has regulatory approval.

To increase support for the EU partner commercializing Sixmo (Probuphine), you have a foundation built on past agreements. Titan Pharmaceuticals previously expected to receive approximately $1.1 million from milestone and royalty payments related to Sixmo starting in the second half of 2021 from its partner, Molteni, and Accord Healthcare Europe. The European Commission approved Sixmo in June 2019 for substitution treatment in the EU.

For the Canadian market, Knight Therapeutics Inc. holds the exclusive right to distribute PROBUPHINE™. Health Canada authorized Probuphine in April 2018. As of 2021, Probuphine was listed for reimbursement on the federal Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plans. Specific data on the current base of Probuphine prescribers in Canada isn't immediately available, but the product has been available coast to coast.

The $1 Million private placement completed in April 2025 with Blue Harbour Asset Management L.L.C-FZ, alongside a subsequent $600,000 placement in June 2025, provides capital for market access initiatives. As of June 30, 2025, Titan Pharmaceuticals, Inc. reported cash of approximately $2.8 million. This cash position is intended to fund planned operations through the second quarter of 2026.

The core advantage to emphasize for ProNeura is its continuous delivery profile. Probuphine delivers buprenorphine continuously for six months following a single procedure. This contrasts with daily oral OUD treatments. Historically, the Wholesale Acquisition Cost (WAC) for Probuphine in the US was US $4,950 for a six-month course of treatment.

Here are the relevant balance sheet figures as of June 30, 2025:

Market penetration efforts should focus on maximizing utilization within the existing approved patient pool:

• Increase support for the EU partner commercializing Sixmo to boost licensed revenue.
• Target the existing base of Probuphine prescribers in Canada to maximize current market share.
• Use the $1 Million April 2025 financing to fund market access initiatives in existing licensed territories.
• Emphasize ProNeura's six-month continuous delivery advantage over daily oral OUD treatments.

Titan Pharmaceuticals, Inc. (TTNP) - Ansoff Matrix: Market Development

Market development for Titan Pharmaceuticals, Inc. centers on expanding the reach of its ProNeura platform, primarily through its lead product, Probuphine (known as Sixmo in the EU), into new international territories.

Secure new licensing agreements for Probuphine/Sixmo in high-need regions like Australia or Latin America.

• Probuphine continues to be commercialized in the European Union (as Sixmo) and Canada by existing partners.
• Titan was entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory.
• The company is exploring strategic collaborations to expand patient access in potential markets overseas.

Partner with international organizations to introduce the ProNeura platform to emerging markets for OUD treatment.

Titan Pharmaceuticals, Inc. is a development-stage biotechnology company focused on its ProNeura long-term, continuous drug delivery technology. The ProNeura platform is designed for chronic diseases where consistent, around-the-clock blood levels of medication may improve outcomes.

Initiate regulatory filings for Probuphine in Asian markets, leveraging existing EU approval.

Requirements governing product licensing in countries outside the European Union and the United States, such as those in Asia or Latin America, vary from country to country.

Present ProNeura data at global addiction medicine conferences to attract new geographic partners.

The company has a history of presenting Probuphine Phase 3 data at the American Society of Addiction Medicine (ASAM) Annual Conference.

The company's recent financial activity in 2025 reflects a focus on funding development programs following strategic corporate changes. In June 2025, Titan Pharmaceuticals, Inc. completed a private placement of Series C Convertible Preferred Stock, raising an aggregate of $600,000. This placement involved 60,000 shares at a conversion price of $3.40.

The following table summarizes the known geographic commercialization status for the Probuphine/Sixmo product based on its EU approval.

Titan Pharmaceuticals, Inc. (TTNP) - Ansoff Matrix: Product Development

You're looking at how Titan Pharmaceuticals, Inc. (TTNP) plans to drive growth by improving its existing product platform, ProNeura, which is a proprietary, long-term, continuous drug delivery system. This system uses a small, solid implant made from ethylene-vinyl acetate (EVA) to maintain steady drug levels for chronic conditions. The focus here is on Product Development-making better versions of what they already have or developing new applications for the core technology.

Accelerating Nalmefene Implant Development

The Nalmefene implant for Opioid Use Disorder (OUD) prevention is a key near-term focus. Titan Pharmaceuticals, Inc. received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase 1 study of this six-month or longer subdermal formulation on July 5, 2022. This clearance was supported by prior work, including a NIDA grant that provided funds for non-clinical studies. The aggregate potential expense reimbursement from the initial NIDA grant, which started in September 2018, was approximately $8.7 million, building on an initial two-year grant of approximately $6.7 million.

To push this forward, Titan Pharmaceuticals, Inc. secured capital in the near term. They completed a private placement of convertible preferred stock on June 27, 2025, raising $600,000. The goal is to use this capital to accelerate the clinical path for the Nalmefene implant.

Formulation Optimization with New Capital

The ProNeura technology requires precise formulation to hit target release profiles. For instance, historical work on a nalmefene/EVA implant showed that a 25 wt.% coated rod achieved an in vivo release rate of 0.29 mg/day/rod sustained over 6 months in rats. You need to dedicate capital to ensure the human formulation for OUD meets the target duration, which is stated as six months or longer.

Here's a quick look at the financial anchor for this work:

The strategy requires dedicating a portion of that $600,000 raise specifically to Nalmefene formulation optimization. What this estimate hides is the exact allocation percentage, but the cash infusion provides the runway to execute on this critical pre-clinical/early clinical step.

Developing Next-Generation ProNeura Implants

The ProNeura platform has shown potential for even longer durations, which is the next logical step in product development for chronic CNS disorders. Early animal data for a different ProNeura implant candidate suggested a potential delivery duration of up to one year. The current target for the Nalmefene implant is six months or longer, but the R&D effort must look beyond that.

The development focus includes:

• Targeting a 12-month duration implant for OUD.
• Exploring the ProNeura platform for other CNS disorders.
• Leveraging historical data showing sustained release through Day 84 in animal models for one candidate.

Exploring New Drug Candidates for ProNeura

The ProNeura technology itself is the asset, not just the Nalmefene molecule. Titan Pharmaceuticals, Inc. has explored pairing it with other agents. For example, they manufactured a prototype implant containing the kappa opioid agonist peptide, TP-2021 (TP-2021 - ProNeura), following its acquisition in October 2020. This shows a clear path to exploring new drug candidates within the existing OUD and addiction markets, or adjacent CNS areas.

Key development activities related to new pairings include:

• Assessing feasibility of delivering the kappa opioid agonist peptide (TP-2021) via ProNeura.
• Focusing on chronic conditions where steady-state delivery is beneficial.

Finance: draft 13-week cash view by Friday.

Titan Pharmaceuticals, Inc. (TTNP) - Ansoff Matrix: Diversification

Advance the Kappa Opioid Receptor Agonist (TP-2021) implant for chronic pruritus through Phase 1 trials.

The acquisition of the kappa opioid agonist peptide, TP-2021, from JT Pharmaceuticals, Inc. occurred in October 2020. Early non-clinical studies in February 2021 showed potent antipruritic activity in a mouse model for moderate to severe pruritus. Titan Pharmaceuticals, Inc. estimated that the Investigational New Drug (IND) submission could be accomplished within 18 to 24 months following the February 2021 data. The company had previously made a first milestone payment under the JT Agreement in January 2022 for successful completion of a proof-of-concept study in an animal model.

Establish a new strategic partnership to co-develop the TP-2021 product for the dermatology market.

Titan Pharmaceuticals, Inc. granted Knight Therapeutics Inc., or Knight, an exclusive license to commercialize a product, as detailed in an amended agreement. The company also entered into a research and option license agreement in October 2021 with the MUSC Foundation for Research Development, or MUSC FRD, related to tetrapeptide kappa-opioid receptor agonist compounds. The structure of the business combination closing on October 1, 2025, involved each issued and outstanding share of Titan common stock being automatically converted into one (1) Black Titan Corporation Ordinary Share (BTTC).

Seek non-dilutive grant funding, similar to the NIDA support for Nalmefene, for the TP-2021 program.

For the Nalmefene implant program, the National Institute on Drug Abuse (NIDA) awarded Titan Pharmaceuticals, Inc. a two-year grant of approximately $6.7 million starting in September 2018, with the first year funded at approximately $2.7 million. The potential aggregate expense reimbursement for that program increased to approximately $8.7 million due to changes in grant award terms. Separately, in October 2021, Titan Pharmaceuticals, Inc. received an approximately $500,000 grant from the Bill and Melinda Gates Foundation for a different ProNeura implant application.

Identify and in-license a new drug candidate for a non-CNS chronic condition, like hypothyroidism, for ProNeura delivery.

The corporate structure as of October 12, 2025, reported 1.33M shares outstanding. The Q2 2025 Earnings Per Share (EPS) was -$0.65, with a trailing EPS of -$2.95. Financing activities in 2025 included a $1 Million private placement in April and a $600,000 private placement in June. The market capitalization as of December 2025 was reported as $6.13M.

• TP-2021 ProNeura implants were formulated and tested in an animal model.
• The ProNeura technology is intended for up to six months or longer delivery.
• The merger consideration was one (1) Black Titan Corporation Ordinary Share for each share held.
• Trading of TTNP common stock ceased at the close of business on October 1, 2025.
• The combined company's shares commenced trading on October 2, 2025.